ArticleProceedings of the National Academy of Sciences of the United States of America2019
Deprivation of glutamine in cell culture reveals its potential for treating cancer.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A phenotype-based cell culture model of melanoma cells that persist as residual disease after therapies leading to recurrence.Research square · 2026Article
- Norovirus NS1/2 protein increases glutaminolysis for efficient viral replication.PLoS pathogens · 2024Article
- Phase separations in oncogenesis, tumor progressions and metastasis: a glance from hallmarks of cancer.Journal of hematology & oncology · 2023Review
- Inhibition of the proline metabolism rate-limiting enzyme P5CS allows proliferation of glutamine-restricted cancer cells.Nature metabolism · 2023Article
- Cell culture-derived extracellular vesicles: Considerations for reporting cell culturing parameters.Journal of extracellular biology · 2023Article
- Glutamine regulates the cellular proliferation and cell cycle progression by modulating the mTOR mediated protein levels of β-TrCP.Cell cycle (Georgetown, Tex.) · 2023Article
- In vitro culture of bovine fibroblasts using select serum-free media supplemented with Chlorella vulgaris extract.BMC biotechnology · 2023Article
- Molecular targeted therapy: A new avenue in glioblastoma treatment.Oncology letters · 2023Review
- Microfabricated polymer-metal biosensors for multifarious data collection from electrogenic cellular models.Microsystems & nanoengineering · 2023Article
- Targeting fat mass and obesity-associated protein mitigates human colorectal cancer growthFrontiers in oncology · 2023Article
- Loss of Heterozygosity forInternational journal of molecular sciences · 2022Article
- Oncogenic KRAS mutations enhance amino acid uptake by colorectal cancer cells via the hippo signaling effector YAP1.Molecular oncology · 2021Article
- Review
- LncRNA GIRGL drives CAPRIN1-mediated phase separation to suppress glutaminase-1 translation under glutamine deprivation.Science advances · 2021Article
- Evaluation of Antitumor Efficacy of Chitosan-Tamarind Gum Polysaccharide Polyelectrolyte Complex Stabilized Nanoparticles of Simvastatin.International journal of nanomedicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growth-stimulating capacity of calf serum (CS) in cell culture reaches a maximum of 10% with Balb 3T3 cells, remains at a plateau to 40% CS, and declines steeply to 100% CS. Growth capacity can be largely restored to the latter by a combination of cystine and glutamine. Glutamine is a conditionally essential amino acid that continues to function at very low concentrations to support the growth of nontransformed cells, but transformed cells require much larger concentrations to survive. These different requirements hold true over a 10-fold variation in background concentrations of CS and amino acids. The high requirement of glutamine for transformed cells applies to the development of neoplastically transformed foci. These observations have given rise to a novel protocol for cancer therapy based on the large difference in the need for glutamine between nontransformed and transformed cells. This protocol would stop the cumulative growth and survival of the transformed cells without reducing the growth rate of the nontransformed cells. The results call for studies of glutamine deprivation as a treatment for experimental cancer in rodents and clinical trials in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.